Astro-Med, Inc. 10-Q Filing Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Astro-Med, Inc., a manufacturer of test and measurement, specialty printer, and neurophysiology products. The report covers the three-month and nine-month periods ended November 1, 2003. The company operates through three segments: Test & Measurement (T&M), QuickLabel Systems (QLS), and Grass-Telefactor (G-T).
Key Financial Metrics
| Metric | Three Months Ended Nov 1, 2003 | Nine Months Ended Nov 1, 2003 |
|---|---|---|
| Net Sales | $14,386,000 | $41,623,000 |
| Gross Profit | $5,926,000 (41.2% Margin) | $16,792,000 (40.3% Margin) |
| Operating Income | $1,059,000 | $2,523,000 |
| Net Income | $901,000 ($0.20 Basic EPS) | $2,217,000 ($0.52 Basic EPS) |
| Cash & Equivalents | $4,457,000 | $4,457,000 (End of Period) |
| Operating Cash Flow (9mo) | $2,041,000 | |
| Debt/Liquidity | No long-term debt reported. $3.5M unsecured bank line of credit available (none drawn). |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 22% in the quarter and 15% for the nine-month period compared to the prior year. International sales were a primary driver, up 38% in the quarter and 28% for the nine months.
- Profitability Turnaround: The company returned to profitability, reporting Net Income of $901,000 for the quarter compared to a Net Loss of $311,000 in the prior year quarter. Operating income improved from a loss of $460,000 to a profit of $1,059,000.
- Margin Expansion: Gross profit margins improved to 41.2% (quarter) and 40.3% (nine months) from 37.2% and 36.1% respectively in the prior year, driven by sales mix and volume.
- Expense Management: R&D expenses decreased 16% in the quarter and 8% for the nine months due to workforce reductions implemented in January 2003. SG&A expenses increased slightly due to higher sales volume.
- Segment Performance:
- QLS: Sales up 27% (quarter); turned from a loss to a profit.
- G-T: Sales up 38% (quarter); turned from a loss to a profit.
- T&M: Sales down 1% (quarter); profit margin improved to 15%.
Outlook, Risks, and Management Commentary
- Liquidity: Cash and securities available for sale totaled $10.06 million at quarter-end. The company received $1.88 million from stock option exercises.
- Working Capital: Accounts receivable collection cycle slowed to 61 days from 53 days. Inventory turns improved to 3.1 times.
- Dividends: The company declared dividends of $0.04 per share for the quarter ($0.12 for the nine months).
- Risks: Management cites risks including declining demand in defense/aerospace markets, competition in specialty printers and neurophysiology, foreign currency exchange rate fluctuations, and the ability to integrate acquisitions.
- Restructuring: A restructuring plan implemented in the prior fiscal year resulted in $490,000 in charges. The remaining accrual for severance was $27,514 as of November 1, 2003.
Investor Verification Checklist
- Verify the sustainability of the 22% quarterly sales growth, particularly the heavy reliance on international channels (38% increase).
- Monitor the slowing accounts receivable collection cycle (61 days vs. 53 days) for potential cash flow impacts.
- Assess the long-term impact of the 16% reduction in R&D spending on future product innovation and competitiveness.
- Review the specific drivers of the T&M segment's 1% sales decline to ensure it does not signal broader market weakness in the core defense/aerospace sector.
- Confirm the utilization of the $3.5 million credit line remains low, indicating strong internal liquidity.